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Abstract
Background: Motivated by the challenges in assessing physician-level cancer screening performance and the negative
impact of misclassification, we propose a method (using mammography as an example) that enables confident assertion of
adequate or inadequate performance or alternatively recognizes when more data is required.
Methods: Using established metrics for mammography screening performance–cancer detection rate (CDR) and recall rate
(RR)–and observed benchmarks from the Breast Cancer Surveillance Consortium (BCSC), we calculate the minimum volume
required to be 95% confident that a physician is performing at or above benchmark thresholds. We graphically display the
minimum observed CDR and RR values required to confidently assert adequate performance over a range of interpretive
volumes. We use a prospectively collected database of consecutive mammograms from a clinical screening program
outside the BCSC to illustrate how this method classifies individual physician performance as volume accrues.
Results: Our analysis reveals that an annual interpretive volume of 2770 screening mammograms, above the United States’
(US) mandatory (480) and average (1777) annual volumes but below England’s mandatory (5000) annual volume is
necessary to confidently assert that a physician performed adequately. In our analyzed US practice, a single year of data
uniformly allowed confident assertion of adequate performance in terms of RR but not CDR, which required aggregation of
data across more than one year.
Conclusion: For individual physician quality assessment in cancer screening programs that target low incidence
populations, considering imprecision in observed performance metrics due to small numbers of patients with cancer is
important.
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Introduction
Metrics used to evaluate the quality of a cancer screening
program often parallel performance characteristics of randomized
controlled trials (RCTs) that have demonstrated a mortality
benefit and have thereby established the efficacy of the test–
typically detection rates and false positives [1]. For screening tests
that require physician expertise, like mammography [2,3] and
colonoscopy [4,5], variability of practice has been observed and
undoubtedly compromises the quality and efficacy of the overall
program. There is a large corpus of literature demonstrating the
difficulties in accurately identifying outliers, particularly on the
individual physician level [6–12]. However, policy-makers and
health systems are increasingly requiring reporting of screening
performance on the physician level, for example in United States
(US), via the Physician Quality Reporting System [13]. Accurate
performance assessment in cancer screening is particularly
challenging because disease incidence is low. An attractive method
of identifying outlier physicians, if available, is comparison to an
absolute cut-off level generated from national benchmarks or
guidelines [6,14]. However, one caveat to this method of
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performance evaluation is that observed performance values may
be imprecise if generated from small (and therefore highly
variable) populations inherent in low volume practice [6,15].
Mammography screening may be the best studied screening
test, perhaps due to rigorous performance of RCTs, development
of large, high-quality, population-based data sets and subsequent
quality legislation. For these reasons, we use mammography as our
example. The Mammography Quality Standards Act (MQSA),
established in 1992 in the US, requires each mammography
facility to have a medical audit system for follow-up and outcome
analysis but stops short of requiring that physicians meet specific
performance criteria [15]. Other nations with breast cancer
screening programs have a spectrum of systems of quality
assurance. However most systems use at least two metrics, cancer
detection rate (CDR) and recall rate (RR), to compare and classify
individual physician performance for mammography screening
(individual physician CDR and RR measurements will be
henceforth called ‘‘observed performance values’’). Recommended
screening mammography performance ranges (henceforth called
‘‘benchmarks’’) have also been established, refined, and docu-
mented in the literature [15–19] by using population-based
reference distributions [19] or consensus methods [15]. For
example, Carney et al. published consensus levels of minimally
acceptable performance for CDR (above 2.5/1000) and RR
(between 5 and 12%) and found that 28.4% of a community-based
sample of US interpreting physicians the National Cancer Institute
Breast Cancer Surveillance Consortium (BCSC) were below this
benchmark for CDR and 49.1% were outside the range for RR
[15]. CDR and RR are closely related and should be considered
together because higher true positive rates (estimated by CDR) are
generally correlated with higher false positive rates (estimated by
RR) [20–22].
Observed performance values for many physicians in the BCSC
were based on a small number of mammograms, especially those
performed on women with cancer, possibly leading to misclassi-
fication of some physicians based on imprecise estimates. The
volume of interpreted mammograms directly influences the size of
the confidence interval around observed performance values and
these confidence intervals should be considered in the evaluation
of individual physicians. Although interpretative volume has been
recognized as a source of inaccuracy when assessing performance
benchmarks historically [15], judgments based on observed
performance values have not considered volume [19]. We develop
a method for asserting adequate or inadequate screening
performance or identifying when more data (higher volume) is
required for individual physician-level performance evaluation,
and demonstrate this method for screening mammography.
Materials and Methods
Our Institutional Review Board did not require that this
HIPAA-compliant, retrospective quality-assurance project involve
informed consent. We define CDR and RR benchmarks based on
the BCSC reference distribution derived from seven mammogra-
phy registries in the US [15,19].
Cancer detection rate (CDR) is the number of true positive
screening mammograms divided by the total number of screening
mammograms performed [23]. In the BCSC, CDR for the middle
80% of physicians ranges from 2.4/1000 to 7.0/1000 with a
median of 4.4/1000 [19]. Higher CDR is always desirable with an
upper limit constrained by the incidence of disease. Low CDR
values typically reveal suboptimal performance. For clarity, we
define the benchmark threshold as a limit (selected based on a
reference distribution–the10th or 90th percentile of the BCSC, in
our case) that the confidence interval (selected based on the desired
level of confidence–95%, in our case) of an individual physician’s
performance value must not overlap in order to be deemed
adequate. For CDR, we define the benchmark threshold as the
10th percentile of the BCSC reference distribution, which is 2.4/
1000.
Recall rate is the number of positive screening mammograms
(true positive+false positive) divided by the total number of
screening examinations interpreted [23]. Of note, the lower limit
of total positives should ideally be characterized by the trade-off
between true positives and total positives (CDR vs. RR). In other
words, a low RR is only ‘‘bad’’ if it results in low CDR. We
therefore focus on detecting RRs that are too high, assuming a low
RR that is ‘‘bad’’ will be identified by a low CDR. The middle
80% of BCSC physicians had recall rates between 4.4% and
16.8% with a median of 9.7% [19]. For RR, we define the
benchmark threshold as the 90th percentile of the BCSC reference
distribution, which is 16.8%.
We divide screening interpretive performance into 3 categories:
1) met benchmark ‘‘with confidence’’ (adequate performance)
meaning all the values in the confidence interval for the individual
performance value meet or exceed the benchmark threshold, 2)
uncertain performance meaning the 95% confidence interval
overlaps the benchmark threshold, and 3) did not meet benchmark
‘‘with confidence’’ (inadequate performance) meaning that all
the values in the confidence interval for the individual perfor-
mance value fall short of the benchmark threshold.
Clinical Data
In order to validate our approach, we felt it important to
analyze our framework on a practice not included in the BCSC
population. Therefore, we analyzed consecutive screening mam-
mograms performed at our institution (also in the US) from 1/1/
Table 1. BI-RADS* final assessment categories with associated recommendation.
Category Definition Recommendation
0 Needs additional imaging evaluation Additional imaging
1 Negative None (routine mammography)
2 Benign finding None (routine mammography)
3 Probably benign finding Short-interval follow-up (6 months)
4 Suspicious abnormality Biopsy
5 Highly suggestive of malignancy Biopsy
*BI-RADS Version 4 [22].
doi:10.1371/journal.pone.0089418.t001
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2006 to 12/31/2008. All mammographic findings were prospec-
tively described and recorded (at the time of mammography
interpretation) by the interpreting physician using the Breast
Imaging Reporting and Data System (BI-RADS) assessment
categories–Table 1. We included physicians who read more than
480 mammograms per year (corresponding to the volume
mandated by MQSA [24]) in the 3 years that we analyzed. Four
physicians met our inclusion criteria; all were MQSA certified with
5–15 years of experience and 3 were fellowship trained.
Since demographic factors like age, family history of breast
cancer, personal history of breast cancer, breast density, and
comparison with prior mammography [25–27] have repeatedly
been shown to influence clinical outcomes for screening mam-
mography, we measured these parameters to understand the
underlying demographics of our population and to compare to the
BCSC reference population [19].
Outcomes
We calculated cancer detection rate and recall rate as per BI-
RADS methodology (also used in the BCSC data) on an individual
physician level [19,23]. Our institutional Cancer Center Registry
serves as the reference standard for each mammography
examination [28]. A positive mammogram (recall) is a mammo-
gram with an initial BI-RADS assessment of 0, 4, or 5 based on
routine screening views. A detected cancer is a diagnosis of
invasive breast cancer or ductal carcinoma in situ (DCIS) within
12 months following a positively interpreted screening mammo-
gram examination.
Statistical Analysis
We propose a graphical method to illustrate the classification of
performance into three categories (adequate, uncertain, and
inadequate) based observed performance values and interpretive
volume, for a given benchmark threshold. Performance categories
are defined by first calculating a 95% confidence interval (CI) for
the observed performance and then assessing whether the
benchmark threshold lies above, within, or under the 95% CI.
We used the Wilson score confidence interval method with
continuity correction [29] to compute two-sided confidence
intervals for the binomial proportions CDR and RR. We derived
equations (Appendix) for the minimum (or maximum) perfor-
mance value that provides 95% confidence that a physician is
performing adequately for any specified volume. From these
graphs, we obtained the screening mammography volume
Figure 1. Defining adequate performance based on volume. Plots demonstrate our method for constructing curves by using the benchmark
threshold as the limit of 95% confidence based on volume: (A) CDR performance levels are established using 2.4 as the lower boundary for 95% CI of
adequate performance (CIs shown) and the upper boundary for inadequate performance (CIs not shown). This methodology shows (indicated with a
black dot) that a volume of 2770 is required to confidently assert the CDR benchmark median of 4.4/1000 is adequate; (B) RR performance levels are
established using 16.8 as the upper boundary for 95% CI of adequate (CI shown) and inadequate (CI not shown) performance. A volume of 120
(indicated with a black dot) is required to confidently assert the RR benchmark median of 9.7% is adequate. Plots define regions of adequate,
uncertain, and inadequate performance for (B) CDR and (D) RR.
doi:10.1371/journal.pone.0089418.g001
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required to assert with confidence that achievement of the
benchmark median equates to adequate performance [19]. Since
the CDR is a small proportion and may thus be imprecisely
estimated, we obtained coverage probabilities small proportions
and may thus be imprecisely estimated, we obtained coverage
probabilities [30] to assess any possible discrepancy between the
nominal confidence interval and the actual coverage probability–
details are covered in the Appendix and illustrated graphically in
the Appendix figures (4a and 4b). Statistical computations were
done in R 2.15.2 [31] with the binom.coverage() function with the
binom package [32].
Results
Graphical representations of the observed performance values
required to provide 95% confidence of adequate or inadequate
performance given our selected benchmark threshold and a range
of volumes are shown in Figures 1a for CDR and 1b for recall rate.
A volume of 2770 screening mammograms is required to
confidently assert that a CDR of 4.4/1000 (the benchmark
median) equates to adequate performance (Figure 1a–value shown
as black circle denoted by an arrow). At this level of performance
and volume, the lower bound of the 95% confidence interval
meets the benchmark threshold of 2.4/1000, as defined in the
methods. The volume required to confidently assert that the
benchmark median for RR (9.7%) is much lower at 120 screening
mammograms (Figure 1b– value shown as black circle denoted by
an arrow).
During the 3 year time period we analyzed clinical data (from
outside the BCSC), 30,363 screening mammograms were
performed for 18,069 women. We compare our study population
to the BCSC population in Table 2. The mean age of our
population was 56.5 (range= 22–96; standard deviation = 11.12)
years. Similar to the BCSC population, the majority of screening
examinations, 83.5% (27,389 of 32,793) were performed in
women within the typical screening age range of 40–69 years
with the minority of women outside this range: 2.4% (795 of
32,793) younger than 40 years and 13.5% (795 of 32,793) older
than 70 years.
Based on this clinical data we analyzed both CDR and RR over
three consecutive years. The average yearly volume for the four
included physicians was 1918 screening mammograms per year
per physician. Plotting observed performance values as volume
increases (Figure 2a) demonstrates that below approximately 3000
mammograms, observed CDR performance values resided in the
uncertain region because confidence intervals consistently overlap
the benchmark threshold. However, as volume increased, all
physicians succeeded in achieving a performance value in the
adequate range. On the other hand, observed RR performance
values quickly settled in the adequate range (Figure 2b).
Analysis of clinical data from one non-BCSC practice demon-
strates that physicians often appear to be underperforming if a
single year is viewed in isolation. Out of 12 annual measures of
CDR (three for each physician), only 5 demonstrated adequate
performance and 7 were in the uncertain range (Figure 3).
Furthermore, each physician had at least one annual observed
performance value below the benchmark median of 4.4/1000
(n= 9) and half (2 of 4) of the physicians had an annual observed
performance value below the level defined for adequate CDR
performance in the literature, 2.5/1000 [15] and the benchmark
Table 2. Distribution of study population.
No Cancer (%) Cancer (%) Total (%) Compare (%)*
Number of Mammograms
Age Groups
,30 20 0.1 0 0.0 20 0.1 0.1
30–39 727 2.4 2 1.2 729 2.4 4.7
40–49 8205 27.2 24 14.8 8229 27.1 29.3
50–59 10,339 34.2 45 27.8 10,384 34.2 28.9
60–69 6796 22.5 52 32.1 6848 22.6 19.1
70–79 3132 10.4 26 16.0 3158 10.4 13.6
.80 982 3.3 13 8.0 995 3.3 4.2
Family History of Breast Cancer
Yes 5818 19.3 46 28.4 5864 19.3 15.2
No 23,775 78.7 114 70.4 23,889 78.7 84.8
Unknown 608 2.0 2 1.2 610 2.0 17.4
Personal History of Breast Cancer
Yes 3071 10.2 74 45.7 3145 10.4 6.3
No 27,130 89.8 88 54.3 27,218 89.6 93.7
Comparison films available
Yes 24,484 81.1 143 88.3 24,627 81.1 89.2
No 5717 18.9 19 11.7 5736 18.9 10.8
Self-reported symptoms
Yes 1132 3.7 21 13.0 1153 3.8 3.6
No 29,069 96.3 141 87.0 29,210 96.2 96.4
*According to Rosenberg, et al. [19].
doi:10.1371/journal.pone.0089418.t002
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threshold 2.4/1000 [19] (Figure 3–physician A, year 2 and
physician C, year 3). However, all 4 physicians showed adequate
performance in at least one year and, most importantly, showed
adequate performance when all three years were aggregated.
Discussion
A physician performing a cancer screening test is expected to
have a high detection rate while simultaneously maintaining a low
false positive rate in order to reap the mortality benefits of early
detection while simultaneously minimizing harms. Variability of
practice diminishes screening program efficacy [2–5,33] and
powerfully motivates physician-level performance evaluation and
quality improvement initiatives. However, due largely to low
disease incidence, performance diverging from benchmarks may
reflect either poor performance or stochastic variation; therefore,
without considering volume and variability, substantive rates of
physician misclassification is a real risk.
We use mammography with associated national benchmark
data (the BCSC reference distribution) as an example to establish
combinations of volume and performance that are adequate with
certainty, inadequate with certainty, or uncertain and thus require
more data. We found that much larger volumes are required to
confidently classify physicians based on CDR vs. RR; given cancer
detection is a much rarer event than recall. For physicians with
observed performance values at the benchmark median, volumes
of 2770 screening mammograms for CDR compared to only 120
screening for RR are required to confidently assert their
performance is adequate. Importantly, below this volume,
physicians must have observed performance values above the
benchmark median to confidently assert adequate performance.
The average annual screening interpretive volume for a large
sample of physicians in the US was 1777 mammograms [34] in
agreement with the average of 1918 screening mammograms per
year, per physicians in our practice; both substantially less than the
2770 required for robust CDR estimates. However, recommended
volumes in other programs like the National Health Service Breast
Cancer Screening Program (with a threshold annual volume of
5000 cases) surpasses this level. [35].
By applying our method to physicians outside the BCSC, we
find that assessing annual observed performance values to judge
CDR for screening mammography without considering volume
(i.e. variability) is perilous, because observed measures for
individual physicians may fall below the benchmark threshold by
chance in a given year. In fact, this occurred for two out of four
physicians (half of our non-BCSC sample) when annual perfor-
mance values were viewed without considering their confidence
intervals, despite adequate performance when larger volumes for
the same physicians were aggregated (thereby decreasing the
variability of observed performance values). Based on established
benchmark thresholds in the literature, (e.g. 2.5/1000 [15])
applied to the observed performance measures without consider-
ing variability in these measures (i.e., the confidence intervals),
these annual observed performance measures might have triggered
quality improvement initiatives, possibly unnecessarily. On the
other hand, pooling data over time for more precise estimates may
generate observed performance values that are less reflective of
current skills. Future investigation on this topic will hopefully
determine the best balance of classification confidence level and
meaningful quality improvement. For example, a quality im-
provement program could use clinical performance as the initial
evaluation framework (recognizing that higher confidence levels
will result in a larger proportion of radiologist being classified in
the ‘‘uncertain’’ zone), then further assess possible underperfor-
mers in an enriched environment with an artificially elevated event
rate–in mammography, a higher proportion of cancers than
expected in the clinical setting–for further evaluation and
improvement monitoring (understanding the difficulties of emu-
lating true performance accuracy in a test setting [36]).
We demonstrate that performance assessment errors are much
more likely for CDR than for RR because of low incidence of
breast cancer–between 2–10 cancers per thousand women [37].
While the challenge of demonstrating statistical differences due to
low event rate in cancer screening has been recognized in the
context of clinical trials [10,11,37] and practice-level performance
accuracy assessment [6,15], we extend this cautionary theme to
physician-level performance measurement and also provide an
intuitive graphical solution to avoid misclassification based on
insufficient volume.
Our method exists in the context of a growing body of literature
that catalogues the challenges of identifying physician outliers [38]
and advances methods to address these challenges [6,11,39]. Some
Figure 2. Individual physician performance assessment based
on volume. Plots of (A) CDR and (B) RR for the 4 included radiologists
at 6 volumes from 500 examinations (then at 1000 and subsequently
1000 exam increments) to the maximum volume read over the 3 years
or 5000 total (whichever was least).
doi:10.1371/journal.pone.0089418.g002
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prior literature evaluates whether a metric is accurate in
establishing physician performance relative to other physicians
using a technique called ‘‘reliability’’ (i.e. primarily evaluating
variation within a pool of providers) [39]. Rather, we have chosen
to use a benchmark population (the BCSC) to develop an absolute
performance requirement against which we judge performance
and associated measurement confidence.
We recognize that our choice of benchmark threshold values (at
the 10th and 90th percentiles of the BCSC reference distributions)
and confidence level (95%) is somewhat ad-hoc. We do not
contend that this choice is ‘‘correct,’’ just reasonable and useful for
illustrative purposes. Our choices might optimally be more or less
strict depending on the values, financial resources, and workforce
considerations of the health system or population. Perhaps a
screening program might rather use a 99% (wider) confidence
interval for observed performance values thereby creating a
stricter standard for classifying someone as adequate or inade-
quate. This would result in more physicians being in the uncertain
zone, which would require more data or some other type of review
to determine if performance is adequate. Using an 80% (narrower)
confidence interval for observed performance values would more
easily classify someone as adequate or inadequate, with fewer
physicians in the uncertain zone. The exact values prescribed are
not the point of our manuscript. Our methodology is intended to
support any reference distribution, selected benchmark threshold
(or consensus-developed performance range), and confidence
interval considered appropriate for a given screening program
[15]. While our ultimate goal in this manuscript is to provide a
method and graphical presentation that is intuitive to individual
physicians in the pursuit of fair and accurate performance
assessment, further work on thresholds for particular settings will
be important.
Our method focuses primarily on the impact of volume and
incidence on whether a physician should be classified as having
adequate or inadequate performance based on an observed
performance value from a finite sample of patients. Differences
in patient population and specifically disease incidence may
influence performance measures [40]. We do not emphasize the
possible influence of differences in patient population or practice
characteristics for individual physicians here because this was
beyond the scope of our goals. However, for this very reason, we
are careful to demonstrate that the individual physicians in our
analysis were practicing in an environment similar to the BCSC
(Table 2), which sampled a large cohort of physicians in a range of
practice settings with diverse patient populations.
Figure 3. Annual observed performance values as compared to aggregated data. Annual CDR for each individual radiologist are shown on
this bar graph with performance values and lower bound 95% CI summarized below the bar graph. The fourth bar for each physician represents
performance over the 3 years of the study period aggregated (‘‘Agg’’) into a consolidated performance metric. Performance values in th first row in
italics and bold represent performance values that would be characterized as inadequate using previously published benchmark thresholds.
doi:10.1371/journal.pone.0089418.g003
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Our results establish a general method for classifying physicians
performing screening studies based on comparing observed
performance values to benchmarks. Our method enables confident
assertion of adequate or inadequate performance for some
individuals and prompts further data collection for others. For
our example, screening mammography, we find that one year of
data is likely not enough to accurately assess individual physician
performance, except for particularly high volume readers. These
conclusions likely will apply to other screening programs;
therefore, caution is warranted when assessing screening perfor-
mance measures, particularly at the physician-level. As healthcare
enters an era of ‘‘pay-for-performance,’’ and scrutiny of individual
physician performance increases [41], development of analytic
methods and evaluation programs that consider the statistical
variation of observed performance values for screening will help
avoid erroneously penalizing or rewarding physicians.
Supporting Information
Figure S1 CDR performance estimates create a saw-
tooth appearance for the benchmark threshold because
cancers detected must reflect whole numbers. The
continuity correction becomes negligible for N.3000 screening
mammograms. Curves derived using the Poisson distribution
illustrating the effect of the continuity correction.
(EPS)
Figure S2 RR performance estimates create a sawtooth
appearance but it becomes smoother sooner due to
higher event rate. The continuity correction can be safely
ignored even for low N, because the recall rate (RR) is higher than
the cancer detection rate (CDR). Curves derived using the Poisson
distribution illustrating the effect of the continuity correction.
(EPS)
Materials S1 Online Data Supplement: Statistical meth-
odology.
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